Clinical Trial

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test the hypothesis that a combined Immuno-Oncology (IO) strategy would see efficacy in a virally driven cancer like Nasopharyngeal Carcinoma (NPC). Hence, this is a combination study of nivolumab and ipilimumab in Epstein-Barr virus (EBV) driven nasopharyngeal carcinoma.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2017-03-26; most recent amendment 2026-06-17.
Status change: Recruiting → Active, Not Recruiting 2026-06-17
Status change: Not Yet Recruiting → Recruiting 2017-04-03
Trial Details
NCT Number NCT03097939
Lead Sponsor National Cancer Centre, Singapore
Collaborators: National University of Singapore, National Taiwan University Hospital
Conditions Nasopharyngeal Carcinoma
Enrollment 113 participants
Start Date 2017-03-31
Primary Completion 2027-04-05 (estimated)
Study Completion 2027-04-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-22